irinotecan liposome + temozolomide + fluzoparib

This is a combination regimen consisting of three agents: **Irinotecan Liposome** is a topoisomerase I inhibitor encapsulated in a lipid bilayer vesicle, designed to enhance tumor delivery and reduce systemic toxicity compared to conventional irinotecan. It works by inhibiting the enzyme topoisomerase I, leading to DNA damage and cancer cell death. The nanoliposomal formulation allows for prolonged circulation and increased accumulation in tumor tissue via the enhanced permeability and retention effect[3][4][8]. **Temozolomide** is an oral alkylating agent that methylates DNA at the O6 position of guanine, resulting in cytotoxicity primarily through induction of DNA strand breaks during replication. **Fluzoparib** is an oral small molecule PARP inhibitor that blocks poly(ADP-ribose) polymerase enzymes involved in single-strand DNA break repair, thereby enhancing cytotoxicity especially in cells with defective homologous recombination repair mechanisms[1]. This combination is being investigated as second-line therapy for recurrent or metastatic Ewing sarcoma after progression on first-line chemotherapy[2]. The rationale for combining these agents lies in their complementary mechanisms targeting different aspects of cancer cell survival and DNA repair.

Brand names

Onivyde (for irinotecan liposome)

Other names

nal–IRI (for irinotecan liposome)irinotecan hydrochloride trihydrate, liposomal formulationfluzoparib